No Data
William Blair Maintains UniQure NV(QURE.US) With Buy Rating
William Blair analyst Sami Corwin maintains $uniQure NV(QURE.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 36.4% and a total average return of -4.4% over the pas
Sector Update: Health Care Stocks Mixed Premarket Monday
Health care stocks were mixed premarket Monday as the Health Care Select Sector SPDR Fund (XLV) was 0.3% higher and the iShares Biotechnology ETF (IBB) was down 0.2% recently. SpringWorks Therapeutics
UniQure: Genezen Will Enter Strategic Supply Agreements for UniQure's Clinical Portfolio and CSL's Comml HEMGENIX Pdt >QURE
UniQure: Genezen Will Enter Strategic Supply Agreements for UniQure's Clinical Portfolio and CSL's Comml HEMGENIX Pdt >QURE
Genezen To Acquire UniQure's Commercial Gene Therapy Manufacturing Operations In Lexington, MA QURE
Genezen To Acquire UniQure's Commercial Gene Therapy Manufacturing Operations In Lexington, MA QURE
UniQure Shares Rise After US FDA Grants Regenerative Medicine Advanced Designation for Huntington's Treatment
uniQure (QURE) shares rose 8% in recent Monday trading after the company obtained the regenerative medicine advanced therapy designation from the US Food and Drug Administration for AMT-130 to treat H
UniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington's Disease
~ Designation based on 24-month interim Phase I/II clinical data for AMT-130 announced in December 2023 ~ ~ AMT-130 is the first therapeutic candidate to receive RMAT Designation for Huntington's disease ~ ~ Receiving